---
title: A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
date: '2024-05-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38804514/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240528181550&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Felzartamab had acceptable safety and side-effect profiles
  in patients with antibody-mediated rejection. (Funded by MorphoSys and Human Immunology
  Biosciences; ClinicalTrials.gov number, NCT05021484; and EUDRACT number, ...'
disable_comments: true
---
CONCLUSIONS: Felzartamab had acceptable safety and side-effect profiles in patients with antibody-mediated rejection. (Funded by MorphoSys and Human Immunology Biosciences; ClinicalTrials.gov number, NCT05021484; and EUDRACT number, ...